AdJane Announces its Official Launch as a Leader in Vaccine Adjuvants

For more information about AdJane and our commitment to advancing public health please visit www.AdJane.com

About the company

AdJane specializes in the development of vaccine adjuvants aimed at enhancing vaccine efficacy. At the heart of AdJane's innovations lies our proprietary Ada-24 adjuvant. This adjuvant has been developed through a strategic collaboration and long-term partnership with Intravacc, a pioneer and leader in translational vaccinology. Ada-24 is based on and leverages the features of Outer Membrane Vesicles (OMVs), derived from gram-negative bacteria and further detoxified, resulting in a safe adjuvant already tested in humans. These nanoparticles are a powerful tool in enhancing the immune response due to their versatile and adaptable nature. Various studies have shown that the inclusion of our proprietary Ada-24 adjuvant elicits a broad immune response, outperforming conventional adjuvants.

Adjane will continue its efforts to develop novel adjuvants and looks forward to partnership opportunities towards commercializing Ada-24.

For additional inquiries, please contact us at [email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/adjane-announces-its-official-launch-as-a-leader-in-vaccine-adjuvants-302287752.html